Table 3.
Combinatorial studies between miRNAs and chemio/radiotherapy.
| miRNA | Cancer | Sample Type | Combinatorial Treatment | Effect | Ref. |
|---|---|---|---|---|---|
| miR-24 | LCa | LSCC cell lines (Hep-2, AMC-HN-8) | Overexpressed miR-24 (pGCMV/miR-24) + Radiation |
Enhanced radiosensitivity: Suppresses cell proliferation and induces cell apoptosis | [36] |
| miR-196a | HNSCC | HNC cell line (HN30) | miR-196a knockdown (miR-196a sponge plasmid) + Radiation |
Enhanced radiosensitivity: Decreases cell viability | [119] |
| miR-138-2-3p | LCa | LCa stem cells (originated from Hep-2) | Overexpressed miR-138-2-3p (100 nM miR-138-2-3p mimic) + Radiation |
Enhanced radiosensitivity: Inhibits cell proliferation, viability, invasion and induces cell apoptosis, cell cycle arrest and DNA damage | [122] |
| miR-218 | Oral cancer | Oral cancer stem cells | Overexpressed miR-218 (pLV-miR-218) + Radiation |
Enhanced radiosensitivity: Decreases cell viability | [123] |
| miR-181a | TSCC | DDP-resistant TSCC cell line (originated from CAL27) | Overexpressed miR-181a (miR-181a mimic) + Cisplatin |
Enhanced chemosensitivity: Decreases IC50 value to cisplatin | [126] |
| miR-222 | OSCC | OSCC cell line (UM1) | miR-222 knockdown (anti-miR-222) + Cisplatin |
Enhanced chemosensitivity: Induces cell apoptosis by up-regulation of pro-apoptotic PUMA expression and reduces cell invasiveness and IC50 value to cisplatin | [127] |
| miR-101-3p | SGACC | SGACC cell lines (SACC-LM, SACC-83) | miR-101-3p knockdown (anti-miR-101-3p) + Cisplatin |
Enhanced chemosensitivity: Inhibits cell growth and induces cell apoptosis | [128] |
| miR-196a | HNC | HNC cell line (CAL27) | miR-196a knockdown (anti-miR-196a) + Cisplatin |
Enhanced chemosensitivity: Promotes cell apoptosis and decreases colony formation | [129] |
LSCC: Laryngeal squamous cell carcinoma; HNSCC: Head and neck squamous cell carcinoma; LCa: Laryngeal cancer; OSCC: Oral squamous cell cancer; SACC: Salivary adenoid cystic carcinoma; TSCC: Tongue squamous cell carcinoma SGACC: Salivary gland adenoid cystic carcinoma; HNC: head and neck cancer; DDP: cisplatin.